152 related articles for article (PubMed ID: 38654028)
21. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
22. Treatment of high-grade gliomas using escalating doses of hypofractionated simultaneous integrated boost-intensity-modulated radiation therapy in combination with temozolomide: A modified Phase I clinical trial.
Ge X; Xue X; Liu H; Wang Y; Xiao Z; Tian L; Chang X; Lin Q; Yu J
J Cancer Res Ther; 2018; 14(7):1482-1491. PubMed ID: 30589027
[TBL] [Abstract][Full Text] [Related]
23. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
[TBL] [Abstract][Full Text] [Related]
24. Randomized controlled study comparing simultaneous modulated accelerated radiotherapy versus simultaneous integrated boost intensity modulated radiotherapy in the treatment of locally advanced head and neck cancer.
Tandon S; Gairola M; Ahlawat P; Rawat S; Aggarwal A; Sharma K; Tiwari S; Karimi AM; Muttagi V; Sachdeva N; Bhushan M
J Egypt Natl Canc Inst; 2018 Sep; 30(3):107-115. PubMed ID: 29960876
[TBL] [Abstract][Full Text] [Related]
25. Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity.
Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
Radiat Oncol; 2017 Aug; 12(1):131. PubMed ID: 28810885
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.
Ney DE; Carlson JA; Damek DM; Gaspar LE; Kavanagh BD; Kleinschmidt-DeMasters BK; Waziri AE; Lillehei KO; Reddy K; Chen C
J Neurooncol; 2015 Mar; 122(1):135-43. PubMed ID: 25524817
[TBL] [Abstract][Full Text] [Related]
27. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
Panet-Raymond V; Souhami L; Roberge D; Kavan P; Shakibnia L; Muanza T; Lambert C; Leblanc R; Del Maestro R; Guiot MC; Shenouda G
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):473-8. PubMed ID: 18554821
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of high ipsilateral subventricular zone radiation therapy dose in glioblastoma: a pooled analysis.
Lee P; Eppinga W; Lagerwaard F; Cloughesy T; Slotman B; Nghiemphu PL; Wang PC; Kupelian P; Agazaryan N; Demarco J; Selch MT; Steinberg M; Kang JJ
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):609-15. PubMed ID: 23462418
[TBL] [Abstract][Full Text] [Related]
29. Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.
Gerstein J; Franz K; Steinbach JP; Seifert V; Rödel C; Weiss C
Strahlenther Onkol; 2011 Nov; 187(11):722-8. PubMed ID: 22037649
[TBL] [Abstract][Full Text] [Related]
30. Re-irradiation of recurrent glioblastoma using helical TomoTherapy with simultaneous integrated boost: preliminary considerations of treatment efficacy.
Arpa D; Parisi E; Ghigi G; Savini A; Colangione SP; Tontini L; Pieri M; Foca F; Polico R; Tesei A; Sarnelli A; Romeo A
Sci Rep; 2020 Nov; 10(1):19321. PubMed ID: 33168845
[TBL] [Abstract][Full Text] [Related]
31. Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer.
Jereczek-Fossa BA; Maucieri A; Marvaso G; Gandini S; Fodor C; Zerini D; Riva G; Alessandro O; Surgo A; Volpe S; Fanetti G; Arculeo S; Zerella MA; Parisi S; Maisonneuve P; Vavassori A; Cattani F; Cambria R; Garibaldi C; Starzyńska A; Musi G; De Cobelli O; Ferro M; Nolè F; Ciardo D; Orecchia R
Med Oncol; 2018 Nov; 36(1):9. PubMed ID: 30483899
[TBL] [Abstract][Full Text] [Related]
32. Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide.
Badiyan SN; Markovina S; Simpson JR; Robinson CG; DeWees T; Tran DD; Linette G; Jalalizadeh R; Dacey R; Rich KM; Chicoine MR; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):877-85. PubMed ID: 25257812
[TBL] [Abstract][Full Text] [Related]
33. Integration method of 3D MR spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boost.
Ken S; Vieillevigne L; Franceries X; Simon L; Supper C; Lotterie JA; Filleron T; Lubrano V; Berry I; Cassol E; Delannes M; Celsis P; Cohen-Jonathan EM; Laprie A
Radiat Oncol; 2013 Jan; 8():1. PubMed ID: 23280007
[TBL] [Abstract][Full Text] [Related]
34. Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.
Harris G; Jayamanne D; Wheeler H; Gzell C; Kastelan M; Schembri G; Brazier D; Cook R; Parkinson J; Khasraw M; Louw S; Back M
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):802-810. PubMed ID: 28602411
[TBL] [Abstract][Full Text] [Related]
35. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
Iuchi T; Hatano K; Kodama T; Sakaida T; Yokoi S; Kawasaki K; Hasegawa Y; Hara R
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):793-800. PubMed ID: 24495592
[TBL] [Abstract][Full Text] [Related]
36. Impact of subventricular zone irradiation on outcome of patients with glioblastoma.
Mathew BS; Kaliyath SB; Krishnan J; Bhasi S
J Cancer Res Ther; 2018; 14(6):1202-1206. PubMed ID: 30488830
[TBL] [Abstract][Full Text] [Related]
37. Intraoperative radiotherapy for glioblastoma: an international pooled analysis.
Sarria GR; Sperk E; Han X; Sarria GJ; Wenz F; Brehmer S; Fu B; Min S; Zhang H; Qin S; Qiu X; Hänggi D; Abo-Madyan Y; Martinez D; Cabrera C; Giordano FA
Radiother Oncol; 2020 Jan; 142():162-167. PubMed ID: 31629553
[TBL] [Abstract][Full Text] [Related]
38. Intensity-Modulated Radiotherapy versus Three-Dimensional Conformal Radiotherapy in Definitive Chemoradiotherapy for Cervical Esophageal Squamous Cell Carcinoma: Comparison of Survival Outcomes and Toxicities.
Chen NB; Qiu B; Zhang J; Qiang MY; Zhu YJ; Wang B; Guo JY; Cai LZ; Huang SM; Liu MZ; Li Q; Hu YH; Li QW; Liu H
Cancer Res Treat; 2020 Jan; 52(1):31-40. PubMed ID: 31048664
[TBL] [Abstract][Full Text] [Related]
39. Comparison of radiation regimens in the treatment of Glioblastoma multiforme: results from a single institution.
Azoulay M; Santos F; Souhami L; Panet-Raymond V; Petrecca K; Owen S; Guiot MC; Patyka M; Sabri S; Shenouda G; Abdulkarim B
Radiat Oncol; 2015 Apr; 10():106. PubMed ID: 25927334
[TBL] [Abstract][Full Text] [Related]
40. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
Ciammella P; Galeandro M; D'Abbiero N; Podgornii A; Pisanello A; Botti A; Cagni E; Iori M; Iotti C
Clin Neurol Neurosurg; 2013 Sep; 115(9):1609-14. PubMed ID: 23453151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
